Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With CD19+ B-cell leukemia.

Start Date23 May 2017

Sponsor / Collaborator

Beijing Imunopharm Technology Co., Ltd.Startup

NCT02640209

/ TerminatedEarly Phase 1IIT

Pilot Trial of Autologous T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (CART19) in Combination With Ibrutinib in Patients With Relapsed or Refractory CD19+ CLL or SLL

Open-label pilot study to determine safety and efficacy of CART-19 cells in combination with ibrutinib. The target dose will be 1-5x10xE8 CART-19 transduced cells administered via split dosing: 10% on Day 1, 30% on Day 2, 60% on Day 3. 15 evaluable subjects (adults) with relapsed or refractory CLL/SLL who have achieved partial response or stable disease on ibrutinib therapy will be eligible to receive CART-19 therapy.

Start Date29 Jan 2016

Sponsor / Collaborator

University of Pennsylvania

NCT01747486

/ CompletedPhase 2IIT

Dose Optimization Trial of Autologous T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (CART-19) in Patients With Relapsed or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)

This is a randomized, open-label, parallel group study to determine the optimal dose of CART-19 cells (autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCR Zeta and 4-1 BB co-stimulatory domains) of the two dose levels being assessed (1-5x10e8 vs. 1-5x10e7 CART-19 cells). This trial will be conducted in two stages.

Start Date02 Jan 2013

Sponsor / Collaborator

University of Pennsylvania

100 Clinical Results associated with CD19 Positive B-Cell Chronic Lymphocytic Leukemia

100 Translational Medicine associated with CD19 Positive B-Cell Chronic Lymphocytic Leukemia

0 Patents (Medical) associated with CD19 Positive B-Cell Chronic Lymphocytic Leukemia

Literatures (Medical) associated with CD19 Positive B-Cell Chronic Lymphocytic Leukemia

01 Nov 2021·JCO Precision Oncology

Rapid and Deep Remission Induced by Blinatumomab for CD19-Positive Chronic Myeloid Leukemia in Lymphoid Blast Phase

Author: Hutchinson, Lloyd ; Higgins, Anne W. ; Bledsoe, Jacob R. ; Gerber, Jonathan M. ; Patel, Shyam A.

01 Feb 2020·Gene TherapyQ3 · MEDICINE

Transposon-mediated generation of CAR-T cells shows efficient anti B-cell leukemia response after ex vivo expansion

Q3 · MEDICINE

Article

Author: Bonecker, Simone ; Batista-Silva, Leonardo Ribeiro ; Abdo, Luiza ; Marques, Luisa Vieira Codeço ; Viegas, Mariana ; de Sousa, Priscila ; Alves-Monteiro, Viviane ; Chicaybam, Leonardo ; Monte-Mór, Bárbara ; Bonamino, Martín Hernán

CAR-T-cell therapy has shown considerable advance in recent years, being approved by regulatory agencies in US, Europe, and Japan for the treatment of refractory patients with CD19+ B-cell leukemia or diffuse large B-cell lymphoma. Current methods for CAR-T-cell production use viral vectors for T-cell genetic modification and can take up to 15 days to generate the infusion product. The development of simple and less costly manufacturing protocols is needed in order to meet the increasing demand for this therapy. In this present work, we generated 19BBz CAR-T cells in 8 days using a protocol based on the non-viral transposon-based vector Sleeping Beauty. The expanded cells display mostly a central memory phenotype, expressing higher levels of inhibitory receptors when compared with mock cells. In addition, CAR-T cells were cytotoxic against CD19+ leukemia cells in vitro and improved overall survival rates of mice xenografted with human RS4;11 or Nalm-6 B-cell leukemias. Infused CAR-T cells persisted for up to 28 days, showing that they are capable of long-term persistence and antitumor response. Altogether, these results demonstrate the effectiveness of our protocol and pave the way for a broader application of CAR-T-cell therapy.

01 Oct 2018·Cancer CellQ1 · MEDICINE

Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting

Q1 · MEDICINE

Article

Author: David S. Pitcher ; Xiaolin Xiao ; Katerina Goudevenou ; Mohammed Suhail Chaudhry ; Kyriaki Petevi ; Antonia Rotolo ; Olivier Dubois ; Kikkeri Naresh ; John Maher ; Carolina Kachramanoglou ; Valentina S. Caputo ; Monika Holubova ; Anastasios Karadimitris ; Sandra Iles ; Nicoleta Baxan

Chimeric antigen receptor anti-CD19 (CAR19)-T cell immunotherapy-induced clinical remissions in CD19⁺ B cell lymphomas are often short lived. We tested whether CAR19-engineering of the CD1d-restricted invariant natural killer T (iNKT) cells would result in enhanced anti-lymphoma activity. CAR19-iNKT cells co-operatively activated by CD1d- and CAR19-CD19-dependent interactions are more effective than CAR19-T cells against CD1d-expressing lymphomas in vitro and in vivo. The swifter in vivo anti-lymphoma activity of CAR19-iNKT cells and their enhanced ability to eradicate brain lymphomas underpinned an improved tumor-free and overall survival. CD1D transcriptional de-repression by all-trans retinoic acid results in further enhanced cytotoxicity of CAR19-iNKT cells against CD19⁺ chronic lymphocytic leukemia cells. Thus, iNKT cells are a highly efficient platform for CAR-based immunotherapy of lymphomas and possibly other CD1d-expressing cancers.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

CD19 Positive B-Cell Chronic Lymphocytic Leukemia

Basic Info

Related

Analysis